| Pharmacist-led Hepatitis C Management (NCT04322981) | University Health Network, Toronto | 2022-04-13 |
| CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers (NCT04980157) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-01 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects (NCT04309734) | Atea Pharmaceuticals, Inc. | 2021-10-01 |
| Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection (NCT05092074) | National Taiwan University Hospital | 2021-10-01 |
| Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men (NCT04156945) | Public Health Service of Amsterdam | 2021-09-14 |
| Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study (NCT05452187) | Hospital Mutua de Terrassa | 2021-03-12 |
| HCV Reinfection in HD Patients Achieving SVR (NCT04732832) | National Taiwan University Hospital | 2021-02-01 |
| Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women (NCT04852614) | Ain Shams University | 2020-12-01 |
| DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV (NCT04317729) | Foundation for Innovative New Diagnostics, Switzerland | 2020-01-30 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (NCT04211909) | Gilead Sciences | 2020-01-03 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis (NCT04112303) | Gilead Sciences | 2019-10-16 |
| Prevalence of HCV in HIV-negative MSM (NCT04005248) | Erasmus Medical Center | 2019-10-01 |
| Evaluation Study of HCV RDTs in Fresh Samples (NCT04139941) | Foundation for Innovative New Diagnostics, Switzerland | 2019-07-31 |
| Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C (NCT04035980) | University of La Laguna | 2019-07-05 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection (NCT04019717) | Atea Pharmaceuticals, Inc. | 2019-06-20 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients (NCT04111367) | Ginkgopharma CO., LTD | 2019-04-03 |
| Integrating Hepatitis C Screening With Dried Blood Spot Testing Into Colorectal Cancer Screening (NCT04037046) | University of La Laguna | 2019-03-01 |
| Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection (NCT03820258) | Gilead Sciences | 2019-01-28 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients (NCT04001608) | Ginkgopharma CO., LTD | 2018-10-17 |
| Liver Elastography in Patients Undergoing Treatment for Hepatitis C (NCT03434470) | Haukeland University Hospital | 2018-02-02 |
| Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (NCT03036839) | Gilead Sciences | 2017-06-27 |
| Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study (NCT03118843) | Gilead Sciences | 2017-04-25 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (NCT03074331) | Gilead Sciences | 2017-03-23 |
| Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection (NCT03022981) | Gilead Sciences | 2017-01-26 |
| Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (NCT02994056) | Gilead Sciences | 2017-01-23 |
| Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 (NCT04378608) | Beni-Suef University | 2017-01-05 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis (NCT02996682) | Gilead Sciences | 2016-12-26 |
| Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (NCT02939989) | AbbVie | 2016-11-21 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy (NCT02868242) | Gilead Sciences | 2016-08-28 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (NCT02781558) | Gilead Sciences | 2016-07-29 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (NCT02781571) | Gilead Sciences | 2016-07-27 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen (NCT02822794) | Gilead Sciences | 2016-07-25 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (NCT02728206) | Gilead Sciences | 2016-06-12 |
| A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (NCT02738138) | AbbVie | 2016-05-17 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (NCT02671500) | Gilead Sciences | 2016-04-19 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection (NCT02738333) | Gilead Sciences | 2016-04-12 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (NCT02722837) | Gilead Sciences | 2016-04-04 |
| Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (NCT02639247) | Gilead Sciences | 2015-12-23 |
| Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (NCT02639338) | Gilead Sciences | 2015-12-23 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (NCT02642432) | AbbVie | 2015-12-07 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies (NCT02600351) | Gilead Sciences | 2015-11-11 |
| A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (NCT02510300) | Gilead Sciences | 2015-10-21 |
| Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection (NCT02537379) | Gilead Sciences | 2015-09-15 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (NCT02487030) | Gilead Sciences | 2015-09-07 |
| Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen (NCT02536313) | Gilead Sciences | 2015-07-29 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection (NCT02480712) | Gilead Sciences | 2015-07-01 |
| A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004) (NCT02461563) | Merck Sharp & Dohme LLC | 2015-06-23 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection (NCT02472886) | Gilead Sciences | 2015-06-17 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (NCT02350569) | Gilead Sciences | 2015-05-22 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (NCT02413593) | Gilead Sciences | 2015-04-01 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (NCT02301936) | Gilead Sciences | 2015-03-02 |
| Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 (NCT04382339) | Beni-Suef University | 2015-03-01 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection (NCT02346721) | Gilead Sciences | 2015-02-23 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection (NCT02378935) | Gilead Sciences | 2015-02-17 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection (NCT02378961) | Gilead Sciences | 2015-02-16 |
| A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (NCT02292706) | Gilead Sciences | 2014-12-29 |
| Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study (NCT02300103) | Gilead Sciences | 2014-12-01 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (NCT02249182) | Gilead Sciences | 2014-11-05 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection (NCT02251717) | Gilead Sciences | 2014-10-14 |
| Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection (NCT02220998) | Gilead Sciences | 2014-09-01 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (NCT02219685) | Gilead Sciences | 2014-08-01 |
| Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection (NCT02175758) | Gilead Sciences | 2014-07-07 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis (NCT02226549) | Gilead Sciences | 2014-07-01 |
| Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (NCT02201953) | Gilead Sciences | 2014-07-01 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (NCT02201901) | Gilead Sciences | 2014-07-01 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection (NCT02201940) | Gilead Sciences | 2014-07-01 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection (NCT02185794) | Gilead Sciences | 2014-06-13 |
| Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis (NCT02128542) | Gilead Sciences | 2014-06-01 |
| Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis (NCT02114151) | Janssen Infectious Diseases BVBA | 2014-04-01 |
| UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C (NCT02123654) | Bristol-Myers Squibb | 2014-04-01 |
| Absolute Bioavailability of BMS-791325 (NCT02112110) | Bristol-Myers Squibb | 2014-04-01 |
| A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (NCT01939197) | AbbVie | 2013-08-30 |
| Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score (NCT07687758) | Siriraj Hospital | 2013-01-01 |
| A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects (NCT01718145) | Bristol-Myers Squibb | 2012-11-01 |
| A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 (NCT01482611) | Janssen R&D Ireland | 2011-11-01 |
| Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials (NCT01428063) | Bristol-Myers Squibb | 2011-09-01 |
| Safety and Efficacy Study in Hepatitis C Patients With PHN121 (NCT01052090) | PhytoHealth Corporation | 2009-09-01 |
| A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies (NCT00872196) | AbbVie (prior sponsor, Abbott) | 2009-04-01 |
| Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation (NCT00668369) | Hospital Clinic of Barcelona | 2008-04-01 |
| Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) (NCT00399672) | University of British Columbia | 2007-06-01 |
| Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver Disease (NCT00630006) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2007-01-01 |
| Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients (NCT00255177) | VGX Pharmaceuticals, LLC | 2005-11-01 |
| Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV (NCT00247884) | University of British Columbia | 2005-06-01 |
| 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response (NCT00308048) | Ullevaal University Hospital | 2004-03-01 |
| Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis (NCT00273247) | National Cancer Institute, Milan | 1998-06-01 |
| Expanded Access to Glecaprevir/ Pibrentasvir (NCT03123965) | AbbVie | |